Madrigal Pharmaceuticals Signs Global siRNA Licensing Deal With Ribo

robot
Abstract generation in progress

Madrigal Pharmaceuticals Inc. has announced a global licensing agreement with Suzhou Ribo Life Science Co. Ltd. to develop six preclinical small interfering RNA programs targeting metabolic dysfunction-associated steatohepatitis (MASH). The deal includes an upfront payment of $60 million to Ribo, with potential milestone payments up to $4.4 billion plus royalties. This agreement expands Madrigal’s pipeline beyond its approved MASH therapy, Rezdiffra, aiming to provide genetically targeted treatment approaches for the liver disease.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)